SCHEMBL25545681

SCHEMBL25545681

COc1ccc(C(=O)C(Br)CC(C)C)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
CYP1A2 P05177 1/20 0.57
GSK3B P49841 1/20 0.50
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
CA1 P00915 5/20 0.47
CA2 P00918 5/20 0.47
KMT2A Q03164 3/20 0.46
LMNA P02545 3/20 0.46
MEN1 O00255 2/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
RAB9A P51151 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2097664 0.83 ALDH1A1 (0.60) ALDH1A1CYP1A2GSK3BCES2CES1
SCHEMBL514175 0.81 ALDH1A1 (0.58) ALDH1A1CYP1A2GSK3BCES2CES1
SCHEMBL4938257 0.81 SLC6A3 (0.54) ALDH1A1GSK3BCES2CES1KMT2A
SCHEMBL23782603 0.81 LMNA (0.44) CYP1A2CA1CA2LMNAMAPT
SCHEMBL585274 0.80 ALDH1A1 (0.66) ALDH1A1CYP1A2GSK3BCES2CES1
SCHEMBL25545461 0.80 PARP10 (0.44) ALDH1A1KMT2ALMNAMEN1PARP10
SCHEMBL5060223 0.80 ALDH1A1 (0.61) ALDH1A1CYP1A2GSK3BCES2CES1
SCHEMBL4932919 0.80 SLC6A2 (0.57) ALDH1A1CYP1A2GSK3BCES2CES1
SCHEMBL7430529 0.79 GSK3B (0.44) ALDH1A1GSK3BCES2CES1CA1
SCHEMBL5685569 0.79 ALDH1A1 (0.64) ALDH1A1CYP1A2GSK3BCES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326746-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2025-10-23 US disclosed
US-12234231-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2025-02-25 US disclosed
EP-4392422-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2024-07-03 EP disclosed
CN-118103368-A EIF4E inhibitors and uses thereof 皮克医疗公司 2024-05-28 CN disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
WO-2023028235-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2023-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326746-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 ALDH1A1 4776/4885CYP1A2 4834/4885GSK3B 1092/4885
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 ALDH1A1 4776/4885CYP1A2 4834/4885GSK3B 1092/4885
US-12234231-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 ALDH1A1 4776/4885CYP1A2 4834/4885GSK3B 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.